Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents

• Published in: Clinical pharmacokinetics 2024-05, Vol.63 (5), p.695-706
• Main Authors: O’Hanlon, Conor J., Sumpter, Anita, Anderson, Brian J., Hannam, Jacqueline A.
• Format: Article
• Language: English
• Subjects: Adolescent; Age; Body composition; Cardiopulmonary Bypass - methods; Cardiotonic Agents - administration & dosage; Cardiotonic Agents - pharmacokinetics; Child; Child, Preschool; Chromatography; Disease prevention; Drug dosages; Female; Heart surgery; Humans; Infant; Infant, Newborn; Infant, Premature; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic Clearance Rate; Milrinone - administration & dosage; Milrinone - pharmacokinetics; Models, Biological; Mortality; Original; Original Research Article; Patients; Pediatrics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Teenagers; Vasodilator Agents - administration & dosage; Vasodilator Agents - pharmacokinetics
• ISSN: 0312-5963; 1179-1926
• DOI: 10.1007/s40262-024-01372-5

Background and Objectives Milrinone is an inotrope and vasodilator used for prophylaxis or treatment of low cardiac output syndrome after weaning from cardiopulmonary bypass (CPB). It is renally eliminated and has an acceptable therapeutic range of 100–300 μg/L, but weight-based dosing alone is associated with poor target attainment. We aimed to develop a population pharmacokinetic model for milrinone from premature neonates to adolescents, and to evaluate how age, renal function and recovery from CPB may impact dose selection. Methods Fifty paediatric patients (aged 4 days to 16 years) were studied after undergoing cardiac surgery supported by CPB. Data from 29 premature neonates (23–28 weeks’ postmenstrual age) treated for prophylaxis of low systemic blood flow were available for a pooled pharmacokinetic analysis. Population parameters were estimated using non-linear mixed effects modelling (NONMEM 7.5.1). Results There were 369 milrinone measurements available for analysis. A one-compartment model with zero-order input and first-order elimination was used to describe milrinone disposition. Population parameters were clearance 17.8 L/70 kg [95% CI 15.8–19.9] and volume 20.4 L/h/70 kg [95% CI 17.8–22.1]. Covariates included size, postmenstrual age and renal function for clearance, and size and postnatal age for volume. Milrinone clearance is reduced by 39.5% [95% CI 24.0–53.7] immediately after bypass, and recovers to baseline clearance with a half-time of 12.0 h [95% CI 9.7–15.2]. Milrinone volume was 2.07 [95% CI 1.87–2.27] times greater at birth than the population standard and decreased over the first days of life with a half-time of 0.977 days [95% CI 0.833–1.12]. Conclusion Milrinone is predominately renally eliminated and so renal function is an important covariate describing variability in clearance. Increasing clearance over time likely reflects increasing cardiac output and renal perfusion due to milrinone and return to baseline following CPB.